Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Overview
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Companies Involved in Therapeutics Development
Biokine Therapeutics Ltd
Chimerix Inc
Juventas Therapeutics Inc
Noxxon Pharma AG
OncoTrap Inc
TikoMed AB
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Drug Profiles
BKT-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dociparstat sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IBsolvMIR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JVS-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
olaptesed pegol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OT-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CXCL12 for WHIM Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CXCL12 for Metastatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Dormant Products
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Discontinued Products
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Product Development Milestones
Featured News & Press Releases
Dec 10, 2019: Chimerix presents updated results from phase 2 clinical trial of DSTAT in refractory myelodysplastic syndrome and acute myeloid leukemia at American Society of Hematology Annual Meeting
Oct 17, 2019: Noxxon Pharma studies combition therapy for brain cancer
Sep 29, 2019: NOXXON presents latest clinical data from phase 1/2 NOX-A12 / Keytruda combition trial at the ESMO Congress
Sep 18, 2019: NOXXON to present latest clinical data from NOX-A12 / Keytruda combition trial at the ESMO Congress
Sep 12, 2019: NOXXON initiates patient recruitment for phase 1/2 Clinical Trial combining NOX-A12 & Radiotherapy for the treatment of Brain Cancer Patients
Jun 24, 2019: NOXXON announces leading intertiol pharma to evaluate NOX-A12 in new indication
Apr 01, 2019: Noxxon presents updated results from phase 1/2 NOX-A12 /Keytruda combition trial at AACR 2019
Mar 04, 2019: TFS Intertiol appointed CRO representative for TIKOMED’s phase 2 study in clinical islet transplantation
Feb 28, 2019: NOXXON to present latest clinical data from NOX-A12 / Keytruda combition trial at the 2019 AACR Annual Meeting
Feb 27, 2019: Noxxon Files application for phase 1/2 clinical trial combining NOX-A12 & radiotherapy for the treatment of Brain Cancer Patients
Dec 14, 2018: NOXXON announces key findings that NOX-A12 plus Keytruda induces an immune response and results in clinical benefit for patients
Dec 10, 2018: NOXXON to present latest clinical data from Nox-A12 / Keytruda combition trial at Esmo Immuno-Oncology Congress
Nov 30, 2018: TIKOMED Granted Permission for Phase 2 Clinical Trial in Islet Cell Transplantation by the Swedish Medical Product Agency
Nov 21, 2018: NOXXON to launch NOX-A12 with radiotherapy clinical trial in patients with brain cancer
Nov 19, 2018: TIKOMED granted permission for phase 2 clinical trial in islet cell transplantation by the Swedish Medical Product Agency
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Biokine Therapeutics Ltd, H2 2019
Pipeline by Chimerix Inc, H2 2019
Pipeline by Juventas Therapeutics Inc, H2 2019
Pipeline by Noxxon Pharma AG, H2 2019
Pipeline by OncoTrap Inc, H2 2019
Pipeline by TikoMed AB, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019